Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure

/in

Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on 31 March 2023 for its second-generation […]

Read more

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases

/in

Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases  Dermatology industry veteran Thibaud Portal, PhD appointed as CEO   London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which […]

Read more

Poolbeg Pharma Plc: Results for the year ended 31 December 2022

/in

Significant milestones reached, well capitalised and positioned for future growth London, UK 30 March 2023 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF “Poolbeg” or the “Company”) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022. Read more…

Read more

iOnctura Awarded UK’s MHRA Innovation Passport For Entry Into Innovative Licensing And Access Pathway (ILAP)

/in

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA). Read more…

Read more

Destiny Pharma – Landmark XF-73 Phase 2 data published in journal

/in

Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients    Brighton, United Kingdom – 24 March 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life […]

Read more
© Optimum Strategic Communications.